<DOC>
	<DOCNO>NCT01761266</DOCNO>
	<brief_summary>E7080-G000-304 multicenter , randomize , open-label , noninferiority Phase 3 study compare efficacy safety lenvatinib versus sorafenib first-line systemic treatment subject unresectable Hepatocellular Carcinoma ( HCC ) .</brief_summary>
	<brief_title>A Multicenter , Open-Label , Phase 3 Trial Compare Efficacy Safety Lenvatinib ( E7080 ) Versus Sorafenib First-Line Treatment Subjects With Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects must confirm diagnosis unresectable HCC follow criterion : Histologically cytologically confirm diagnosis HCC Clinically confirm diagnosis HCC accord American Association Study Liver Diseases ( AASLD ) criterion , include cirrhosis etiology chronic hepatitis B C infection criterion 2 . At least one measurable target lesion accord mRECIST meeting follow criterion : Hepatic lesion 1 . The lesion accurately measure least one dimension great equal 1.0 cm ( viable tumor typical ; long diameter atypical ) , 2 . The lesion suitable repeat measurement Nonhepatic lesion c. Lymph node ( LN ) lesion measure least one dimension great equal 1.5 cm short axis , except porta hepatis LN measure great equal 2.0 cm short axis d. Nonnodal lesion measure great equal 1.0 cm long diameter Lesions previously treat radiotherapy locoregional therapy must show radiographic evidence disease progression deem target lesion . 3 . Subjects categorize stage B ( applicable transarterial chemoembolization [ TACE ] ) stage C base Barcelona Clinic Liver Cancer ( BCLC ) stag system 4 . Adequate bone marrow function , define : Absolute neutrophil count ( ANC ) great equal 1.5 X 10^9/L Hemoglobin ( Hb ) great equal 8.5 g/dL Platelet count great equal 75 X 10^9/L 5 . Adequate liver function , define : Albumin great equal 2.8 g/dL Bilirubin le equal 3.0 mg/dL Aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) less equal 5 X upper limit normal ( ULN ) 6 . Adequate blood coagulation function , define international normalized ratio ( INR ) less equal 2.3 7 . Adequate renal function define creatinine clearance great 40 mL/min calculate per Cockcroft Gault formula 8 . Adequate pancreatic function , define amylase lipase less equal 1.5 X ULN 9 . Adequately control blood pressure ( BP ) 3 antihypertensive agent , define BP le equal 150/90 mm Hg Screening change antihypertensive therapy within 1 week prior Cycle1/Day1 10 . ChildPugh score A 11 . ECOGPS 0 1 12 . Survival expectation 12 week longer start study drug 13 . Males female age least 18 year ( age great 18 year determine country legislation ) time inform consent 14 . Females must lactate pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin [ BhCG ] test minimum sensitivity 25 IU/L equivalent unit BhCG ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 15 . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy bilateral oophorectomy , surgery least 1 month dose ) 16 . Females childbearing potential must unprotected sexual intercourse within 30 day study entry must agree use highly effective method contraception ( e.g. , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 30 day study drug discontinuation . If currently abstinent , subject must agree use double barrier method describe becomes sexually active study period 30 day study drug discontinuation . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week dose must continue use contraceptive study 30 day study drug discontinuation . 17 . Male subject must successful vasectomy ( confirm azoospermia ) female partner must meet criterion ( i.e. , childbearing potential practicing highly effective contraception throughout study period 30 day study drug discontinuation ) . No sperm donation allow study period 30 day study drug discontinuation . 18 . Provide write informed consent 19 . Willing able comply aspect protocol Exclusion Criteria 1 . Imaging finding HCC correspond follow : HCC great equal 50 percent liver occupation Clear invasion bile duct Portal vein invasion main portal branch ( Vp4 ) 2 . Subjects receive systemic chemotherapy , include antiVEGF therapy , systemic investigational anticancer agent , include lenvatinib , advanced/unresectable HCC . Note : Subjects receive local hepatic injection chemotherapy eligible . 3 . Subjects receive anticancer therapy ( include surgery , percutaneous ethanol injection , radio frequency ablation , transarterial [ chemo ] embolization , hepatic intraarterial chemotherapy , biological , immunotherapy , hormonal , radiotherapy ) blood enhance treatment ( include blood transfusion , blood product , agent stimulate blood cell production , eg , granulocyte colonystimulating factor [ GCSF ] ) within 28 day prior randomization 4 . Subjects recover toxicity result prior anticancer therapy , except alopecia infertility . Recovery define less Grade 2 severity per Common Terminology Criteria Adverse Events Version 4.0 ( CTCAE v4.0 ) . 5 . Significant cardiovascular impairment : history congestive heart failure great New York Heart Association ( NYHA ) Class II , unstable angina , myocardial infarction stroke within 6 month first dose study drug , cardiac arrhythmia require medical treatment Screening 6 . Prolongation QTc interval great 480 m 7 . Gastrointestinal malabsorption condition might affect absorption lenvatinib opinion investigator 8 . Bleeding thrombotic disorder use anticoagulant require therapeutic INR monitoring , eg , warfarin similar agent . Treatment low molecular weight heparin factor X inhibitor require INR monitoring permit . Antiplatelet agent prohibit throughout study . 9 . Gastrointestinal bleeding event active hemoptysis ( bright red blood least 0.5 teaspoon ) within 28 day prior randomization 10 . Gastric esophageal varix require interventional treatment within 28 day prior randomization . Prophylaxis pharmacologic therapy ( eg , nonselective betablocker ) permit . 11 . Active malignancy ( except HCC definitively treat melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu cervix ) within past 36 month 12 . Subjects whose target lesion ( ) bone exclude 13 . Meningeal carcinomatosis 14 . Any history current brain subdural metastases 15 . Subjects great 1+ proteinuria urine dipstick test undergo 24hour urine collection quantitative assessment proteinuria . Subjects urine protein great equal 1 g/24 hour ineligible . 16 . Surgical arterialportal venous shunt arterialvenous shunt 17 . Any medical condition opinion investigator would preclude subject 's participation clinical study 18 . Known intolerance lenvatinib sorafenib ( excipients ) 19 . Human immunodeficiency virus ( HIV ) positive active infection require treatment ( except hepatitis virus ) 20 . Any history drug alcohol dependency abuse within prior 6 month 21 . Any subject evaluate either triphasic liver CT triphasic liver MRI allergy contraindication CT MRI contrast agent 22 . Major surgery within 3 week prior randomization schedule surgery study 23 . Subject liver transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Cancer</keyword>
</DOC>